December 21, 2022 | Case studies
272BIO Limited, an innovative animal health company, will be joining the growing cluster of excellence at SRP in mid-2023.
Formed 3 years ago, 272BIO is a biotherapeutics company developing treatments to tackle diseases across animal health.
Antibody therapeutics represent a bio-friendly alternative to the use of antibiotics and other chemicals, potentially harmful to the environment and the food chain.
272BIO uses llama-derived VHH antibody technology with its relatively low production costs in microbial systems to develop highly innovative treatments.
272BIO uses innovative protein design and engineering to produce the best antibody therapeutic drugs for veterinary medicine.
Read more about SRP’s innovative companies in our Annual Review 2022